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OBJECTIVE—Embryos exposed to a diabetic environment in
utero have an increased risk to develop congenital heart malfor-
mations. The mechanism behind the teratogenicity of diabetes
still remains enigmatic. Detrimental effects of glycation products
in diabetic patients have been well documented. We therefore
studied a possible link between glycation products and the
development of congenital cardiovascular malformations. Fur-
thermore, we investigated other possible mechanisms involved
in this pathogenesis: alterations in the levels of vascular endo-
thelial growth factor (VEGF) or phosphorylated Smad2 (the
latter can be induced by both glycation products and VEGF).
RESEARCH DESIGN AND METHODS—We examined the
temporal spatial patterning of the glycation products
N
ε (carboxymethyl)lysine (CML) and methylglyoxal (MG) ad-
ducts, VEGF expression, and phosphorylated Smad2 during
cardiovascular development in embryos from normal and
diabetic rats.
RESULTS—Maternal diabetes increased the CML accumulation
in the areas susceptible to diabetes-induced congenital heart
disease, including the outﬂow tract of the heart and the aortic
arch. No MG adducts could be detected, suggesting that CML is
more likely to be indicative for increased oxidative stress than
for glycation. An increase of CML in the outﬂow tract of the heart
was accompanied by an increase in phosphorylated Smad2,
unrelated to VEGF. VEGF showed a time-speciﬁc decrease in the
outﬂow tract of embryos from diabetic dams.
CONCLUSIONS—From our results, we can conclude that ma-
ternal diabetes results in transient and localized alterations in
CML, VEGF expression, and Smad2 phosphorylation overlapping
with those regions of the developing heart that are most sensitive
to diabetes-induced congenital heart disease. Diabetes 58:
1222–1228, 2009
D
iabetes increases a women’s risk to give birth to
a child with a congenital malformation. New-
borns of mothers suffering from type 1 diabetes
have a two- to sixfold higher risk of developing
congenital malformations (1–3), while that of children
from women with type 2 diabetes is raised with a factor of
3–11 (4–6). The majority of these malformations concern
the cardiovascular system. Epidemiological studies indi-
cate that maternal diabetes is one of the most important
risk factors for the development of congenital heart dis-
ease (CHD) (7). Considering the rapid increase of preg-
nant women with diabetes, the occurrence of maternal
diabetes–induced CHD is a serious and increasing health
problem.
How maternal diabetes induces CHD still remains to be
elucidated. We have studied the involvement of two mech-
anisms causing complications in adult diabetic patients,
being glycation and disturbance of vascular endothelial
growth factor (VEGF) levels, assuming that these might
also harm embryonic tissues and could thereby disturb
embryonic cardiovascular development.
The formation and accumulation of advanced glycation
end products (AGEs) such as N
ε (carboxymethyl)lysine
(CML) and methylglyoxal (MG) adducts are important
pathophysiological mechanisms in the development of
cardiovascular complications in diabetic patients (8). Ac-
cumulation of AGEs has been reported in diabetic patients
suffering from micro- and macrovascular complications
and delayed wound healing (9,10) as well as in diabetic rat
models (11,12). In patients, the occurrence of the compli-
cations could be prevented using pharmacological inhibi-
tors of AGE formation such as aminoguanidine (13,14),
emphasizing the importance of this mechanism in the
development of diabetes complications. In rat embryos
cultured in high-glucose medium, an increase in a major
precursor in the formation of AGEs, i.e., 3-deoxygluca-
sone, was observed (10), indicating a role for glycation in
the development of congenital malformations. Indeed,
high values of A1C during pregnancy do not only indicate
suboptimal glycemic control, they are also related to the
incidence of congenital malformations (15). If their levels
in pregnant women become high (A1C 14.4), malforma-
tions are identiﬁed in 40% of the neonates (16).
To study the impact of glycation on cardiovascular
development, we investigated the presence of the AGEs
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1222 DIABETES, VOL. 58, MAY 2009CML and MG adducts in embryos derived from diabetic
and nondiabetic rats. We used Sprague-Dawley–derived
outbred U (Uppsala) rats, previously noted for a high rate
of congenital malformations in response to maternal dia-
betes (17,18). In addition, we used embryos of the L and B
inbred rat strains derived from U and H rats, respectively.
In the latter strain, diabetic pregnancy did not increase
congenital malformations in the offspring.
A second strong candidate for a role in maternal diabe-
tes–induced CHD is VEGF. For normal embryonic and
cardiovascular development, it is essential that VEGF is
maintained between critical threshold levels. Mice missing
only one allele die at E10.5, displaying abnormal vessels
(19), while also a two- to threefold overexpression of
VEGF results in severe cardiovascular malformations (20).
Malformations of the cardiac outﬂow tract, such as Tetral-
ogy of Fallot, that are increased in the offspring of diabetic
women can be induced by selective knockout of both the
VEGF188 and VEGF164 isoforms in murine embryos and are
related to a local increase of the VEGF120 isoform and
VEGF signaling in the heart (21,22).
Culture of young mouse embryos (E7.5 until E9.5) in
elevated glucose levels resulted in abnormal development
of the vitelline circulation. This phenomenon could be
prevented by the addition of VEGF (23), suggesting that
the effect of elevated glucose on vascular development is
mediated by a downregulation of VEGF. Furthermore,
VEGF plays a role in vascular complications in adults with
diabetes (24), underscoring the importance of ﬁne bal-
anced VEGF levels for vascular tissue.
We studied VEGF expression locally in the developing
heart using in situ hybridization on sections of rat embryos
from dams with or without diabetes.
Disturbance of Smad2 signaling in the fourth pharyngeal
arch artery (PAA) has been linked to arch malformations
in the transforming growth factor (TGF)- knockout mice
model (25). Because both glycation and VEGF inﬂuence
signaling via Smad2 (26,27), we decided to additionally
study the presence of the phosphorylated Smad2 in these
embryos.
RESEARCH DESIGN AND METHODS
Animals. The Uppsala Regional Ethical Committee on Animal Experiments
approved the research protocol including all experimental procedures involv-
ing animals. We used 3-month-old rats from a local colony of outbred U
(Uppsala) Sprague-Dawley rats, previously noted for a high rate of congenital
malformations in response to maternal diabetes (17,18) as well as the L and B
inbred rat strains derived from the U and H rats (a Sprague-Dawley rat strain
more resistant to diabetes-induced congenital malformations), respectively.
All rats were fed a commercial pellet diet (AB Analycen, Lidko ¨ping, Sweden)
and had free access to food and tap water. They were maintained at an
ambient temperature of 22°C with a 12-h light-dark cycle. Introduction of
diabetes in female rats was performed by injecting 40 mg/kg streptozotocin
(Sigma-Aldrich, Uppsala, Sweden) into the tail vein 1 week before mating
commences, i.e., 1–3 weeks before conception. A state of manifest diabetes
(MD) was conﬁrmed 1 week after the injection by the presence of a blood
glucose level exceeding 20 mmol/l (Medisense Glucose Sensor; Abbot Scan-
dinavia AB, Solna, Sweden). The induced level of hyperglycemia was similar
between rats of the susceptible and resistant strains. Diabetic and nondiabetic
(ND) females were caged with males overnight, and conception was veriﬁed
by the presence of sperm in a vaginal smear. The day of a positive vaginal
smear was designated gestational day 0. Pregnancy was interrupted on
gestational day 13, 14, and 16. Embryos and fetuses were ﬁxed in 4% PBS
paraformaldehyde, subsequently dehydrated in graded ethanol, transferred to
xylene, and ﬁnally embedded in parafﬁn. Cardiac morphology was analyzed in
E16 embryos from diabetic (MD) L rats (n  19) and E16 embryos from B-MD
dams (n  16). Data were compared with the U strain embryos, which we
have studied before on both E16 and E18 (18). A total of 24 E13 embryos from
MD and ND dams were used for the analysis of CML and MG adduct formation
and detection of phosphorylated Smad2, being L-ND (n  4), L-MD (n  4),
B-ND (n  4), B-MD (n  4), U-ND (n  4), and U-MD (n  4). At E14, we
studied 13 embryos of L-ND (n  2), L-MD (n  2), U-ND (n  6), and U-MD
(n  3).
Detection of CML and MG adducts. Embryos were serially sectioned at 5
m. Alternated sections were rehydrated and antigen retrieval was performed
using the microwave to enhance staining. Sections were incubated for1ha t
room temperature with a 1:500 dilution of the anti-CML antibody and 1:5
dilution of the antibody directed against MG adducts (28,29). Subsequently,
sections were washed in PBS and incubated for 60 min with a 1:200 diluted
biotinylated horse anti-mouse antibody (ABC Kit; Vector Laboratories, Bur-
lingame, CA) and incubated with ABC according to the recommendations of
the manufacturer.
Detection of phosphorylated Smad2. Immunohistochemistry was per-
formed after the protocol described above, although no microwave enhance-
ment was performed, and the incubation of the sections, with a 1:1,000
dilution of the phosphorylated Smad2 antibody (provided by Prof. Dr. P ten
Dijke, Leiden University Medical Centre, Leiden, the Netherlands), was
preceded by a blocking step using 10% normal goat serum in PBS.
VEGF in situ hybridization. Consecutive transverse sections of 5 m were
rehydrated and post-ﬁxed in 4% paraformaldehyde for 20 min. Subsequently,
they were treated with 20 g/ml Proteinase K (Promega, Leiden, the Nether-
lands) and 4% paraformaldehyde and by 0.1 mol/l triethanolamine-HCl (pH
8.0)  0.25% acetic anhydride. After dehydration, sections were hybridized
overnight at 55°C using sense and anti-sense
35S-radiolabeled VEGF-A RNA
probes that were transcribed using a 451-bp EcoRI/BamHI cDNA clone
encoding for the mouse VEGF-120 isoform (pVEGF2; provided by Dr. G.
Breier, University of Technology, Dresden, Germany). The following morning,
the sections were washed and then coated with Ilford G5 emulsion (Ilfort,
Mobberly, U.K.), in which they were kept at 4°C for 10 days. Finally, the
sections were developed in Kodak D19 (Kodak, Chalon s. Saonne, France)
solution for 4 min, washed, and ﬁxated in Ilford Hypam (Ilfort), counter-
stained with hematoxylin, and mounted with Pertex (Histolab Products,
Goteborg, Sweden). The sections were examined by light microscopy using
dark ﬁeld optics.
Reconstructions. The Amira V3.1 software package (Template Graphics
Software, San Diego, CA) was used to make three-dimensional reconstruc-
tions of day 13 embryos. For the reconstruction, we used 5-m sections every
25 m. Via manual drawing, the cardiovascular lumen and CML
 areas were
color-labeled and rendered for three-dimensional visualization. Embryos were
processed under comparable conditions described above, allowing for a direct
comparison of the reconstructions.
RESULTS
To identify the potential of AGEs in the development of
diabetes-induced CHD, we analyzed the presence and
localization of CML and MG adducts in E13 and E14
embryos from the malformation-prone L and U rat strains
and the resistant B rats with (MD) and without (ND)
diabetes.
At E13, CML was identiﬁed in all the MD offspring of the
malformation-susceptible rats L-MD and U-MD (Fig. 1).
The CML
 area was identiﬁed in the PAAs (Fig. 1B and D).
More precisely, it overlapped with segments derived from
the fourth and sixth PAA and extended just proximal to
the connection to the subclavian arteries. This we have
shown in the three-dimensional reconstruction of the
developing cardiovascular system of an E13 L-MD embryo
(Fig. 2B–D) and its schematic representation indicating
the various PAA segments (Fig. 2A). Formation of CML
also occurred in the vessel wall of the ascending aorta and
pulmonary trunk, where staining was more intense in the
aortic wall than in the pulmonary trunk (compare Fig. 2C
to Fig. 2D). Furthermore, CML
 cells were identiﬁed in the
outﬂow tract myocardium bordering the cushions of the
outﬂow tract (Fig. 2B, blue). CML accumulated in the
cytoplasm rather than in the extracellular matrix. No CML
could be detected in any of the E13 offspring of the L-ND
or in MD or ND embryos derived from the malformation-
resistant B strain (Fig. 3). In embryos of U-ND rats, we
observed a weak CML staining (Fig. 1). Using immunohis-
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any of the embryos at this stage.
At E14, CML was detected in all embryos in the proximal
outﬂow tract myocardium, in the ascending aorta, all
PAAs, the subclavian arteries, the dorsal aorta, the pulmo-
nary trunk, and the pulmonary arteries. CML was also
present in the cushions of the outﬂow tract, where it was
increased in the MD offspring of the U and L rats (Fig. 4B,
D, and F), compared with that in ND embryos or MD
embryos of the resistant B rats (Fig. 4A, C, and E). Again
no MG adducts could be detected using immunohisto-
chemical analysis.
As hyperglycemia inﬂuences VEGF expression and
alterations in the amount of VEGF can disturb cardio-
vascular development, we performed VEGF in situ hy-
bridizations in embryos from ND and MD dams. At E13, a
high expression of VEGF was seen in all myocardial cells
aligning the endocardial cushions of both the inﬂow tract
and the outﬂow tract of the heart, the myocardial cells in
the ventricular septum, and the ﬁbrous tissue protruding
into the base of the atrial septum, the so-called spina
vestibuli. At this stage of development, VEGF expression
was similar in both ND and MD embryos of L, U, or B rats.
E14 ND embryos and the MD embryos of the resistant B
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FIG. 1. CML detection in E13 embryos of the susceptible L and U strain. Immunohistochemical detection of CML is shown in sections derived from
the offspring of rats of the susceptible L and U strain being either nondiabetic (ND) or diabetic (MD). A–D are at the level of the PAA. In E–H,
we can see the presence of CML in the outﬂow tract (which is not yet septated at this stage of development). Ao, aorta; dAo, descending aorta;
EC, endocardial cushions; LVOT, left ventricular outﬂow tract; RVOT, right ventricular outﬂow tract. Scale bars in A–F,6 0m; in G and H, 200
m. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 2. Indication of the localization of CML in a three-dimensional
reconstruction of an E13 embryo from a diabetic L rat. In this Amira
reconstruction (B–D), the position of CML is indicated in purple (when
present in the vessel wall) or blue (when present in the myocardium of
the outﬂow tract). The aorta is indicated in red, the pulmonary trunk
and ductus arteriosus in green, and the myocardium in gray. The
frontal plane (B) illustrates that the CML
 area is partly located in the
myocardium, the outﬂow tract (attached to the endocardial cushion)
indicated in blue, and partly in the vessel wall of the ascending aorta
indicated in purple. The view from the left (C) shows the CML
 area on
the aortic side of the outﬂow tract (arrow) as well as in the PAA
(arrowhead). The view from the right side (D) shows the presence of
CML on the pulmonary side of the outﬂow tract (arrow) and in the
right-sided PAA (arrowhead). In the artist’s impression (A), the loca-
tion of the third PAA (future carotic artery), the fourth PAA (the
left-sided fourth will become part of the aortic arch and the right-sided
fourth will be part of the brachial cephalic artery), and the sixth PAA
(ductus arteriosus) are indicated. The transparent purple indicates the
CML
 area. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
FIG. 3. CML detection in the resistant B strain embryos at E13.
Immunohistochemical shows that there is no CML accumulation in
sections derived from the offspring of rats from the resistant B strain
being either nondiabetic (ND) or diabetic (MD). Sections A and B are
at the level of the PAA and in C and D at the outﬂow tract (which is not
yet septated at this stage of development). Ao, aorta; dAo, descending
aorta; EC, endocardial cushions; LVOT, left ventricular outﬂow tract,
RVOT, right ventricular outﬂow tract. Scale bar  60 m. (A high-
quality digital representation of this ﬁgure is available in the online
issue.)
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that seen on E13. However, a diabetes-induced decrease in
VEGF expression was observed in ﬁve of six MD embryos
derived from the malformation-prone L and U strain. This
decrease in VEGF could be observed in all areas that
normally have a high VEGF expression level (Fig. 5).
Because both glycation products and VEGF inﬂuence
the Smad2 signaling, we analyzed active Smad2 using an
antibody against phosphorylated Smad2. At E13, phos-
phorylated Smad2 was increased in the CML
 positive
vessel wall of the ascending aorta and pulmonary trunk as
well as in the myocardium of the outﬂow tract (Fig. 6D)i n
L and U MD embryos, compared with either the surround-
ing CML
 cells or to the same area from MD-B embryos
(Fig. 6B) or ND offspring. In the PAAs of all embryos, the
level of phosphorylated Smad2 was relatively high com-
pared with other arteries without a clear distinction for
CML
 or CML
 areas.
At E14, phosphorylation of Smad2 overlapped with the
increased CML patterning, which in this stage of develop-
ment was present in the cushions of the outﬂow tract of
the heart (Fig. 6F–H). In addition, phosphorylated Smad2
is higher in the cushions of the E14 MD offspring (Fig. 6H)
than in the ND offspring (Fig. 6F).
The L and B strains are inbred rat strains of which the L
strain is known to present with extra-cardiac malforma-
tions such as micrognatia, cleft palet, or skeletal malfor-
mations, whereas the B strain is more resistant to these
malformations. Cardiovascular anomalies have not been
described in these strains. It was not known if the diabe-
tes-induced facial anomalies were linked to cardiovascular
malformations. We have therefore studied cardiac mor-
phology of E16 L-MD and B-MD embryos and compared
the identiﬁed malformations with those we have previ-
ously characterized in the U strain embryos of E16 and
E18 (18). In the inbred L rats, all MD fetuses had a CHD
compared with 67% in the outbred U-MD offspring. Out-
ﬂow tract anomalies were identiﬁed in 74% of the L-MD
offspring compared with 63% in the U-MD offspring. De-
fects of the fourth PAA were seen in 47% of the L-MD and
22% of the U-MD embryos and sixth PAA defects in 21% of
the L-MD and 11% of the U-MD embryos (Table 1). In the
B-MD offspring resistant to the maternal diabetes–induced
extra-cardiac malformations, the number of cardiovascu-
lar malformations is also considerably lower (Table 1).
From these data, we can conclude that the L rat strain is
susceptible to diabetes-induced CHD comparable to the U
rat strain.
DISCUSSION
At E13, CML accumulation appeared in a small area of the
developing outﬂow tract and in the PAAs in MD embryos
of the susceptible L and U strains. At this developmental
stage, the PAAs are still paired and their remodeling has
not yet started (18). The addition of myocardium from the
secondary heart ﬁeld to the primary heart tube is almost
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FIG. 4. CML detection in E14 embryos. Sections at several levels in the
endocardial cushions of the outﬂow tract show an increase in CML in
the U-MD (B, D, and F) compared with the U-ND (A, C, and E)
offspring. Ao, aorta; PT, pulmonary trunk; EC, endocardial cushion; RV,
right ventricle; RVOT, right ventricular outﬂow tract. Scale bar  200
m. (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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FIG. 5. Diabetes-induced decrease in cardiac VEGF expression as
shown by in situ hybridization. In the E14-ND offspring, VEGF is
abundantly expressed in the myocardium aligning the cushions of the
outﬂow tract of the heart (A), in the ventricular septum (C), and in the
myocardium around the cushions of the inﬂow tract of the heart (C and
E). At E14, we see a diabetes-induced decrease in VEGF expression in
all L-MD embryos (n  2) and in 75% of the four-unit MD embryos (n 
4) in the myocardium aligning the cushions of the outﬂow (B) and
inﬂow tract of the heart (D and F), in the ventricular septum (D). Ao,
aorta; IC, inﬂow tract cushion; LV, left ventricle; RA, right atrium; RV,
right ventricle; SV, sinus venosus. Scale bar  200 m.
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The cells positive for CML on E13 are known to originate
from two cell populations. The most proximal CML
 cells
are secondary heart ﬁeld–derived cells that have migrated
from the splanchnic mesoderm (31,32). The other CML

cells in the ascending aorta and PAA are derived from the
cardiac neural crest cells (32–35). Given the temporal
spatial overlap between CML accumulation and the
development of cardiovascular outﬂow and PAA anom-
alies, it can be postulated that both the addition of
myocardium from the secondary heart ﬁeld and the
function of neural crest cells are hampered in diabetic
pregnancies (17,18,36–38).
The accumulation of CML and the increase in phosphor-
ylated Smad2 at E13 is asymmetric, being higher on the
aortic side than on the side of the pulmonary trunk. This is
exactly opposite to the lacZ expression identiﬁed in the
y96-Myf5-nLacZ-16 transgenic mice, which is predomi-
nantly seen on the side of the pulmonary trunk (39). From
this, Bajolle et al. (39) hypothesize that deviations from the
left/right asymmetry inhibits outﬂow tract rotation and
result in anomalies such as a double outlet right ventricle.
Analogous and asymmetric increase in CML accumulation
might disturb the left/right signaling in MD embryos and
subsequently the rotation of the outﬂow tract, also result-
ing in CHD, such as a double outlet right ventricle that is
frequently seen in our MD offspring (18). Furthermore,
embryos that are heterozygous for both a Smad2 and
nodal mutation (40) show defects in left-right patterning,
resulting in abnormal cardiac looping. This indicates that
also the asymmetric increase in phosphorylated Smad2
(co-localizing with the asymmetric CML increase) in the
E13 MD embryos is likely to play a role in diabetes-
induced congenital heart malformations.
At E14, septation is almost completed and the process
of PAA remodeling is still in progress. Although CML could
be detected in the embryonic vasculature in both MD and
ND offspring of all strains, increased CML was found in the
cushions of the outﬂow tract in the MD offspring of the
susceptible U and L dams. Abnormal cushions as seen on
E14 could lead to congenital heart malformations such as
Tetralogy of Fallot or double outlet right ventricle. We
have previously identiﬁed these malformations in combi-
nation with hypoplastic cushions in the MD offspring of
these rats (18), in which we now show an increase in CML.
CML is an AGE that can be formed on lysine residues in
proteins by a glycoxidation reaction (41). In the embryos
of our study, we failed to detect MG adducts, which are
produced from a glycation reaction. This raises the ques-
tion whether the CML accumulation indicates an increase
in the formation of AGEs or an increase in oxidative stress.
MG adducts–mediated formation of nonenzymatic glyca-
tion did not take place in sufﬁcient amounts. It cannot be
ruled out that other AGEs, which are not detected by the
antibodies used in this study, may play a role in the
formation of CHD. However, we favor the explanation
that, in our model, the increase in CML can be used as a
biomarker for oxidative damage, as has been suggested
before (41,42). We base this opinion on the fact that
antioxidant supplementation reduces the number and se-
verity of the diabetes-induced CHD in the offspring of
these rats (17). In addition, increasing the oxidative stress
by injection of antimycin A in pregnant mice results in
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FIG. 6. (Co)localization of CML and phosphorylated Smad2. In this
ﬁgure, we show the (co)localization of CML and phosphorylated Smad2 in
the developing cardiovascular system. At E13, no CML (A) and no
increase in phosphorylated Smad2 (B) were observed in the outﬂow tract
of the B-MD offspring. In the MD offspring of the susceptible L strain, both
CML (C) and phosphorylated Smad2 (D) were increased in the outﬂow
tract of the heart. At E14, CML is identiﬁed in the endocardial cushions,
although more CML is identiﬁed in the U-MD offspring (G) compared with
the U-ND offspring (E). At the same time, phosphorylated Smad2 is
increased in the cushions of the outﬂow tract in embryos of the MD
offspring (H) compared with those from nondiabetic dams (F). Scale bar
in A–D  60 m and in E–H  200 m. (A high-quality digital represen-
tation of this ﬁgure is available in the online issue.)
TABLE 1
Percentage (numbers) of congenital heart defects in the offspring
of diabetic rats from the susceptible U and L strain and the
resistant B strain
n Normal
Outflow tract
defects
Fourth PAA
defects
Sixth PAA
defects
U-MD 27 37% (9/27) 63% (17/27) 22% (6/27) 11% (3/27)
L-MD 19 0% (0/19) 74% (14/19) 47% (9/19) 21% (4/19)
B-MD 16 81% (13/16) 13% (2/16) 6% (1/16) 0% (0/16)
L-MD and B-MD fetuses were all of E16; the U-MD fetuses were of
E16 and E18 (18).
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an effect that could be diminished by antioxidant supple-
mentation. Furthermore, CHD was reduced by the addi-
tion of antioxidant in chicken embryos in which neural
crest cells were exposed to elevated glucose (37). Next to
these experimental models, it has been shown that women
who gave birth to a child with a CHD have higher levels of
biomarkers for oxidative stress (44). On the basis of these
data, we are convinced that a local glucose-induced in-
crease in oxidative stress, as pointed out by CML, is an
important mechanism in the development of congenital
malformations in the offspring from diabetic pregnancies.
Elevated glucose levels can disturb the cardiovascular
development by inﬂuencing the expression of VEGF (45).
The addition of high glucose concentrations to cultured
mice embryos inhibits endothelial to mesenchymal trans-
formation in the endocardial cushions by a reduction of
VEGF levels (45). In the MD embryos, a clear overlap
between CML accumulation, reduced VEGF expression,
and hypoplastic endocardial outﬂow tract cushions was
identiﬁed. We assume that a decrease in VEGF causes
cushion hypoplasia and the related maldevelopment of the
outﬂow tract (double outlet right ventricle and Tetralogy
of Fallot). In addition to our results, decreased levels of
VEGF were identiﬁed in cultured embryos and in vitro
endocardial cushions after exposure to elevated glucose
(23,45). This negative relation between diabetes and VEGF
expression in the embryo that we and others found is
opposite to data for adult endothelial cells (46,47).
At E14 in the endocardial cushions of the outﬂow tract
of the heart, CML and phosphorylated Smad2 were in-
creased, whereas VEGF expression was decreased. AGEs
can induce Smad2 phosphorylation in vitro and in vivo
(26), and therefore CML might be responsible for the raise
in phosphorylated Smad2. However, VEGF has been re-
ported to inhibit Smad2 phosphorylation (48); therefore, a
reduced level of VEGF in these structures could also relate
to the identiﬁed increase in Smad2 phosphorylation. Al-
though endothelial to mesenchymal transformation can be
increased by TGF/Smad2 signaling (49,50), the hypoplas-
tic appearance of the outﬂow cushions contradicts this
assumption. We assume that the lack of myocardial VEGF
expression is more detrimental for cushion development
than the stimulating effect one might expect from Smad2.
Unfortunately, the pathways for activation and action of
Smad2 are complex, involving interactions with multiple
players, and at this time, it is not possible to fully elucidate
them.
The incidence of full-blown CHD in fetuses (E16)
between the L and U strain clearly reveals their genetic
predisposition for diabetes-induced congenital cardiovas-
cular malformations. The high percentage of CHD in the
MD offspring of the inbred L strain, for which rats were
selected on the basis of extra-cardiac malformations,
implies that there is a link between cardiovascular and
noncardiac congenital malformations. The similarity be-
tween the number and type of malformations identiﬁed in
the L-MD and U-MD fetuses justiﬁes the use of the L strain
next to the U strain for the identiﬁcation of the pathways
involved in diabetes-induced CHD.
In this research, we have provided a novel proof for a
speciﬁc temporal-spatial pattern rather than a general
increase in CML accumulation, suggesting a raise in oxi-
dative stress. The increase in CML and phosphorylated
Smad2 strikingly overlapped with those cardiovascular
regions that are at high risk during development. Further-
more, the hyperglycemia-related decrease in VEGF was
observed in the same regions. We postulate that local
rather than general changes in CML accumulation, Smad2
phosphorylation, and VEGF expression are detrimental for
the developing cardiovascular system in MD embryos.
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